Page last updated: 2024-10-21

4-aminopyridine and Muscular Dystrophy, Facioscapulohumeral

4-aminopyridine has been researched along with Muscular Dystrophy, Facioscapulohumeral in 1 studies

Muscular Dystrophy, Facioscapulohumeral: An autosomal dominant degenerative muscle disease characterized by slowly progressive weakness of the muscles of the face, upper-arm, and shoulder girdle. The onset of symptoms usually occurs in the first or second decade of life. Affected individuals usually present with impairment of upper extremity elevation. This tends to be followed by facial weakness, primarily involving the orbicularis oris and orbicularis oculi muscles. (Neuromuscul Disord 1997;7(1):55-62; Adams et al., Principles of Neurology, 6th ed, p1420)

Research Excerpts

ExcerptRelevanceReference
"Gene analysis for congenital myasthenic syndrome (CMS) revealed a new mutation in the DOK7 gene; the diagnosis of CMS was confirmed."1.40[Beneficial effects of 3,4-diaminopyridine in a 26-year-old woman with DOK7 congenital myasthenic syndrome who was originally diagnosed with facioscapulohumeral dystrophy]. ( Mori-Yoshimura, M; Murata, M; Nakata, T; Nishikawa, A; Ohno, K; Okamoto, T; Oya, Y, 2014)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nishikawa, A1
Mori-Yoshimura, M1
Okamoto, T1
Oya, Y1
Nakata, T1
Ohno, K1
Murata, M1

Other Studies

1 other study available for 4-aminopyridine and Muscular Dystrophy, Facioscapulohumeral

ArticleYear
[Beneficial effects of 3,4-diaminopyridine in a 26-year-old woman with DOK7 congenital myasthenic syndrome who was originally diagnosed with facioscapulohumeral dystrophy].
    Rinsho shinkeigaku = Clinical neurology, 2014, Volume: 54, Issue:7

    Topics: 4-Aminopyridine; Adult; Amifampridine; Diagnosis, Differential; Female; Humans; Menstrual Cycle; Mus

2014